On Thursday, the U.S. Food and Drug Administration approved LENZ Therapeutics, Inc.’s (NASDAQ:LENZ) VIZZ (aceclidine ophthalmic solution, previously known as LNZ100) 1.44%, the first and only ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback